Satoshi Yamashita

Dr. Satoshi Yamashita


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HKHitoshi Kikuchi
Hitoshi Kikuchi
GAGabriele Almer
Gabriele Almer
SYSatoshi Yamashita
Satoshi Yamashita
CGChristelle Guégan
Christelle Guégan
MNMakiko Nagai
Makiko Nagai
SPSerge Przedborski
Serge Przedborski
Mutation in superoxide dismutase-1 (SOD1), which is a cause of ALS, alters the folding patterns of this protein. Accumulation of misfolded mutant SOD1 might activate endoplasmic reticulum (ER) stress pathways. Here we show that transgenic mice expressing ALS-linked SOD1 mutants exhibit molecular alterations indicative of a recruitment of ER's signaling machinery. We demonstrate by biochemical and morphological methods that mutant SOD1 accumulates inside the ER, where it forms insoluble high molecular weight species and interacts with the ER chaperone immunoglobulin-binding protein. These alterations are age- and region-specific, because they develop over the course of the disease and occur in the affected spinal cord but not in the nonaffected cerebellum in transgenic mutant SOD1 mice. Our results suggest a toxic mechanism for mutant SOD1 by which this ubiquitously expressed pathogenic protein could affect motor neuron survival and contribute to the selective motor neuronal degeneration in ALS.

23 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ATAkihito Tanaka
Akihito Tanaka
KWKnut Woltjen
Knut Woltjen
KMKatsuya Miyake
Katsuya Miyake
AHAkitsu Hotta
Akitsu Hotta
MIMakoto Ikeya
Makoto Ikeya
HSHidetoshi Sakurai
Hidetoshi Sakurai
The establishment of human induced pluripotent stem cells (hiPSCs) has enabled the production of in vitro, patient-specific cell models of human disease. In vitro recreation of disease pathology from patient-derived hiPSCs depends on efficient differentiation protocols producing relevant adult cell types. However, myogenic differentiation of hiPSCs has faced obstacles, namely, low efficiency and/or poor reproducibility. Here, we report the rapid, efficient, and reproducible differentiation of hiPSCs into mature myocytes. We demonstrated that inducible expression of myogenic differentiation1 (MYOD1) in immature hiPSCs for at least 5 days drives cells along the myogenic lineage, with efficiencies reaching 70–90%. Myogenic differentiation driven by MYOD1 occurred even in immature, almost completely undifferentiated hiPSCs, without mesodermal transition. Myocytes induced in this manner reach maturity within 2 weeks of differentiation as assessed by marker gene expression and functional properties, including in vitro and in vivo cell fusion and twitching in response to electrical stimulation. Miyoshi Myopathy (MM) is a congenital distal myopathy caused by defective muscle membrane repair due to mutations in DYSFERLIN. Using our induced differentiation technique, we successfully recreated the pathological condition of MM in vitro, demonstrating defective membrane repair in hiPSC-derived myotubes from an MM patient and phenotypic rescue by expression of full-length DYSFERLIN (DYSF). These findings not only facilitate the pathological investigation of MM, but could potentially be applied in modeling of other human muscular diseases by using patient-derived hiPSCs.

1 September 2019 in The Lancet Neurology
Verified
Journal Article
Closed access
MHMichael G Hanna
Michael G Hanna
UBUmesh A Badrising
Umesh A Badrising
OBOlivier Benveniste
Olivier Benveniste
TLThomas E Lloyd
Thomas E Lloyd
MNMerrilee Needham
Merrilee Needham
AAAnthony A Amato
Anthony A Amato

28 January 2016 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
MAM. Azuma
M. Azuma
THT. Hirai
T. Hirai
KYK. Yamada
K. Yamada
SYSatoshi Yamashita
Satoshi Yamashita
YAYusuke Ando
Yusuke Ando
YYY. Yamashita
Y. Yamashita
BACKGROUND AND PURPOSE: Quantitative susceptibility mapping is useful for assessing iron deposition in the substantia nigra of patients with Parkinson disease. We aimed to determine whether quantitative susceptibility mapping is useful for assessing the lateral asymmetry and spatial difference in iron deposits in the substantia nigra of patients with Parkinson disease. MATERIALS AND METHODS: Our study population comprised 24 patients with Parkinson disease and 24 age- and sex-matched healthy controls. They underwent 3T MR imaging by using a 3D multiecho gradient-echo sequence. On reconstructed quantitative susceptibility mapping, we measured the susceptibility values in the anterior, middle, and posterior parts of the substantia nigra, the whole substantia nigra, and other deep gray matter structures in both hemibrains. To identify the more and less affected hemibrains in patients with Parkinson disease, we assessed the severity of movement symptoms for each hemibrain by using the Unified Parkinson9s Disease Rating Scale. RESULTS: In the posterior substantia nigra of patients with Parkinson disease, the mean susceptibility value was significantly higher in the more than the less affected hemibrain substantia nigra (P < .05). This value was significantly higher in both the more and less affected hemibrains of patients with Parkinson disease than in controls (P < .05). Asymmetry of the mean susceptibility values was significantly greater for patients than controls (P < .05). Receiver operating characteristic analysis showed that quantitative susceptibility mapping of the posterior substantia nigra in the more affected hemibrain provided the highest power for discriminating patients with Parkinson disease from the controls. CONCLUSIONS: Quantitative susceptibility mapping is useful for assessing the lateral asymmetry and spatial difference of iron deposition in the substantia nigra of patients with Parkinson disease.

24 July 2015 in Translational Neurodegeneration
Verified
Journal Article
Open access
PDF file
SYSatoshi Yamashita
Satoshi Yamashita
YAYusuke Ando
Yusuke Ando
Amyotrophic lateral sclerosis (ALS) is the most common adult-onset motor neuron disease. It is characterized by neuronal loss and degeneration of the upper motor neurons (UMNs) and lower motor neurons (LMNs), and is usually fatal due to respiratory failure within 3–5 years of onset. Although approximately 5–10 % of patients with ALS have an inherited form of the disease, the distinction between hereditary and apparently sporadic ALS (SALS) seems to be artificial. Thus, genetic factors play a role in all types of ALS, to a greater or lesser extent. During the decade of upheaval, the evolution of molecular genetics technology has rapidly advanced our genetic knowledge about the causes of ALS, and the relationship between the genetic subtypes and clinical phenotype. In this review, we will focus on the possible genotype-phenotype correlation in hereditary ALS. Uncovering the identity of the genetic factors in ALS will not only improve the accuracy of ALS diagnosis, but may also provide new approaches for preventing and treating the disease.

20 March 2017 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
NTNozomu Tawara
Nozomu Tawara
SYSatoshi Yamashita
Satoshi Yamashita
XZXiao Zhang
Xiao Zhang
MKMai Korogi
Mai Korogi
ZZZiwei Zhang
Ziwei Zhang
YAYusuke Ando
Yusuke Ando